ALMS Profile
Alumis Inc. is a clinical-stage biopharmaceutical firm specializing in the innovation and commercialization of therapies for autoimmune diseases. The company is at the forefront of developing cutting-edge treatments targeting severe autoimmune conditions. Its lead candidate, ESK-001, is an allosteric tyrosine kinase 2 (TYK2) inhibitor designed to address complex autoimmune disorders such as plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Additionally, Alumis is advancing A-005, a central nervous system-penetrant allosteric TYK2 inhibitor intended for the treatment of neuroinflammatory and neurodegenerative diseases, aiming to tackle conditions that affect the central nervous system.
Formerly known as Esker Therapeutics, Inc., Alumis Inc. rebranded in January 2022 to better reflect its evolving focus and innovative approach. The company's name change underscores its commitment to pioneering therapeutic solutions in the biopharmaceutical field. Alumis was established in 2021, and despite its relatively recent inception, it has rapidly advanced its research and development pipeline, driven by a robust portfolio of proprietary drug candidates.
Headquartered in South San Francisco, California, Alumis Inc. operates from a strategic location that positions it at the heart of a dynamic biotech ecosystem. The company leverages its cutting-edge research capabilities and industry expertise to push the boundaries of treatment options available for patients suffering from challenging autoimmune and neuroinflammatory conditions. Its dedicated approach to developing novel therapeutics underscores its mission to make significant advancements in the field of biopharmaceuticals.
Alumis Inc.'s innovative efforts are backed by a team of experienced professionals committed to transforming the treatment landscape for autoimmune and neurodegenerative diseases. As it progresses through clinical trials and regulatory processes, the company's strategic vision and scientific expertise aim to deliver breakthrough therapies that address unmet medical needs and improve patient outcomes across multiple therapeutic areas.
|
